Key facts
- This page summarizes Jonathan David Schwartz's Form 4 filing for Tabula Rasa HealthCare, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 14 Nov 2023, 20:59.
Jonathan David Schwartz - 03 Nov 2023 Form 4 Insider Report for Tabula Rasa HealthCare, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 03 Nov 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Nov 2023, 20:59:36 UTC
- Prior SEC filing
- 13 Jun 2023
- Next SEC filing
- 03 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian W. Adams, by Power of Attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan David Schwartz filed Form 4 for Tabula Rasa HealthCare, Inc. on 14 Nov 2023.
Change
- Previous filing in this sequence was filed on 13 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TRHC
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -17,582
- Change %
- -22%
- Price
- Shares after
- 60,806
- Date
- 03 Nov 2023
- Ownership
- Direct
- Footnotes
- F1
TRHC
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -60,806
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Nov 2023
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Jonathan David Schwartz is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among Tabula Rasa HealthCare, Inc. (the "Company"), Locke Buyer, LLC and Locke Merger Sub, Inc., dated August 5, 2023 (the "Merger Agreement"), 17,582 shares of common stock of the Company ("Common Stock") were converted into the right to receive a cash payment of $184,611, representing the product obtained by multiplying (x) the number of shares of Common Stock owned by the reporting person, by (y) the offer price ($10.50).
Footnote F2
Upon the consummation of the Merger, pursuant to the Merger Agreement, 60,806 unvested restricted stock awards ("RSAs") were cancelled and converted into the right to receive a cash payment of $638,463, representing the product obtained by multiplying (x) the aggregate number of shares of Common Stock underlying the RSAs, by (y) the offer price ($10.50).